
Ozempic without the side effects? New drug touted as weight loss game changer
There's no doubt that GLP-1 drugs like Ozempic have been revolutionary — not just for people who want to lower their blood sugar and lose weight but for those who want to control other cravings as well.
Unfortunately, sometimes these benefits come with unsightly downsides such as tooth decay, a droopy face or mouth, a saggy butt and hair loss.
While many of those side effects are due to rapid weight loss — rather than the drugs themselves — the medications are known to cause icky gastrointestinal issues.
People on drugs like Ozempic have complained about some unpleasant side effects, including tooth decay, a droopy face or mouth, a saggy butt and hair loss.
K KStock – stock.adobe.com
Now, a groundbreaking new drug has shown some of the same promise in melting belly fat — without making your stomach churn.
This week in the journal Cell, researchers unveiled a drug — developed by the Sweden biotechnology company Atrogi AB — based on a type of special molecule.
While GLP-1s mimic the GLP-1 hormone the body naturally produces after eating to suppress appetite, this new drug activates metabolism in skeletal muscle.
In a Phase I clinical trial involving 25 people with Type 2 diabetes and 48 healthy humans, the drug was successful at improving blood sugar levels and weight — without those pesky GLP-1 side effects.
Since most GLP-1s are injectables, the fact that this medication comes in tablet form could be groundbreaking to trypanophobes.
Since most GLP-1s are injectables, the fact that this medication comes in tablet form could also be groundbreaking to anyone who is afraid of needles.
í¢í°í½í íÅí¸í°í¸íâíÅ½í° – stock.adobe.com
'This drug represents a completely new type of treatment and has the potential to be of great importance for patients with Type 2 diabetes and obesity,' Shane C. Wright, assistant professor at the Department of Physiology and Pharmacology at Karolinska Institutet in Stockholm, said in a statement.
'Our substance appears to promote healthy weight loss and, in addition, patients do not have to take injections.'
Wright noted that the drug can be used 'as a stand-alone treatment and in combination with GLP-1 drugs.'
This can be a game changer for people who are micro-dosing drugs like Ozempic due to the sky-high costs.
It could also be impactful now that the Food and Drug Administration has cracked down on Ozempic copycats, potentially slimming options for consumers who have come to rely on budget-friendly alternatives.
Finally, researchers say the drug can boost weight loss without negatively influencing muscle mass or overworking the heart — both crucial longevity markers.
'Our results point to a future where we can improve metabolic health without losing muscle mass,' said Tore Bengtsson, a professor at the Department of Molecular Bioscience at Wenner-Gren Institute in Stockholm.
'Muscles are important in both Type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time Magazine
5 hours ago
- Time Magazine
TIME100 Most Influential Companies 2025: Life Time
Life Time's 200-plus locations across the U.S. aren't fancy gyms, insists founder and CEO Bahram Akradi. They're "athletic country clubs," with pools, pickleball, tennis, spas, restaurants and, yes, fitness equipment. Some have coworking space or apartments attached; some are helping old malls reboot. The aim, says Akradi, is to create a 'one-stop shop' where members 'truly trust they can get all aspects of their healthy living and healthy aging.' With that goal of a holistic health experience in mind, Life Time is now rolling out on-site medical clinics that offer nutrition plans, hormone therapy, and GLP-1 prescriptions. The Minnesota-based company's shift to luxury has powered a surge in membership and doubled its stock price since early 2024. More than 1.5 million individual members visited 114 million times in 2024, up 33% from 2022, despite many locations capping membership to give its affluent customers, who pay an average of $224 monthly (plans start at $99), generous personal space.


New York Post
7 hours ago
- New York Post
Ozempic without the side effects? New drug touted as weight loss game changer
There's no doubt that GLP-1 drugs like Ozempic have been revolutionary — not just for people who want to lower their blood sugar and lose weight but for those who want to control other cravings as well. Unfortunately, sometimes these benefits come with unsightly downsides such as tooth decay, a droopy face or mouth, a saggy butt and hair loss. While many of those side effects are due to rapid weight loss — rather than the drugs themselves — the medications are known to cause icky gastrointestinal issues. People on drugs like Ozempic have complained about some unpleasant side effects, including tooth decay, a droopy face or mouth, a saggy butt and hair loss. K KStock – Now, a groundbreaking new drug has shown some of the same promise in melting belly fat — without making your stomach churn. This week in the journal Cell, researchers unveiled a drug — developed by the Sweden biotechnology company Atrogi AB — based on a type of special molecule. While GLP-1s mimic the GLP-1 hormone the body naturally produces after eating to suppress appetite, this new drug activates metabolism in skeletal muscle. In a Phase I clinical trial involving 25 people with Type 2 diabetes and 48 healthy humans, the drug was successful at improving blood sugar levels and weight — without those pesky GLP-1 side effects. Since most GLP-1s are injectables, the fact that this medication comes in tablet form could be groundbreaking to trypanophobes. Since most GLP-1s are injectables, the fact that this medication comes in tablet form could also be groundbreaking to anyone who is afraid of needles. í¢í°í½í íÅí¸í°í¸íâíÅ½í° – 'This drug represents a completely new type of treatment and has the potential to be of great importance for patients with Type 2 diabetes and obesity,' Shane C. Wright, assistant professor at the Department of Physiology and Pharmacology at Karolinska Institutet in Stockholm, said in a statement. 'Our substance appears to promote healthy weight loss and, in addition, patients do not have to take injections.' Wright noted that the drug can be used 'as a stand-alone treatment and in combination with GLP-1 drugs.' This can be a game changer for people who are micro-dosing drugs like Ozempic due to the sky-high costs. It could also be impactful now that the Food and Drug Administration has cracked down on Ozempic copycats, potentially slimming options for consumers who have come to rely on budget-friendly alternatives. Finally, researchers say the drug can boost weight loss without negatively influencing muscle mass or overworking the heart — both crucial longevity markers. 'Our results point to a future where we can improve metabolic health without losing muscle mass,' said Tore Bengtsson, a professor at the Department of Molecular Bioscience at Wenner-Gren Institute in Stockholm. 'Muscles are important in both Type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy.'
Yahoo
11 hours ago
- Yahoo
BioCity's SC0062 gains NMPA breakthrough therapy designation
The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted BioCity's endothelin receptor type A (ETA) antagonist, SC0062, a second breakthrough therapy designation (BTD). This new designation is intended to treat diabetic kidney disease (DKD) with albuminuria and highlights the therapy's potential for chronic kidney disease indications. The BTD was supported by data from the DKD cohort of the Phase II 2-SUCCEED trial, and SC0062 showed major reductions in albuminuria at the 20mg dose against placebo. The safety profile was favourable both as monotherapy and when combined with treatments such as SGLT2 inhibitors, GLP-1 receptor agonists, RAAS inhibitors, insulin and Finerenone. BioCity co-founder and executive president Dr Ivy Wang stated: 'With over 700 million people affected globally, kidney disease represents one of our greatest unmet medical challenges. 'This dual BTD recognition validates SC0062's potential to redefine treatment paradigms across renal diseases. We're accelerating development to deliver this promising therapy to patients worldwide.' The completed 2-SUCCEED programme achieved all efficacy and safety endpoints at 12 and 24-week timepoints for both Immunoglobulin A nephropathy (IgAN) and DKD cohorts. SC0062 may slow CKD progression compared to non-selective treatments while minimising side effects. Preclinical studies have shown that it significantly improved pathological scores in acute and CKD models. The therapy has completed Phase I trials, demonstrating good tolerability, safety and pharmacokinetics without signs of fluid retention. It has now concluded enrolment for both IgAN and DKD cohorts in the Phase II 2-SUCCEED study and the cohorts have met their primary endpoints. With these developments underway, BioCity is initiating two Phase III clinical trials that include SUCCESS-01 (IgAN) and SUCCESS-02 (CKD). "BioCity's SC0062 gains NMPA breakthrough therapy designation" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. 登入存取你的投資組合